-- What are the economics of the PharmAthene relationship with GTC?
Based on the discussion from GTC’s 4Q06 CC (#msg-17607391), I think it’s reasonable to assume that the economics of the PharmAthene relationship are similar to those of GTC's Merrimack relationship, which I’ve estimated at a high-single-digit percentage of end-user product sales (#msg-18566595).
Protexia probably doesn’t have as much sales potential as Merrimack’s MM-093, so the absolute value of the PharmAthene relationship for GTC is probably less than the absolute value of the Merrimack relationship on a risk-adjusted basis. The PharmAthene relationship could nonetheless generate a consequential income stream for GTC, especially if the longshot program in Alzheimer’s disease were ever to pan out.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.